Effect of Sitagliptin and Glimepiride on Pancreatic Beta-Cells during the Treatment of Type-2 Diabetic Mellitus by Statistical Analysis

Main Article Content

Bhaskar Joshi
Praveen Yadav
A. Geetha Bhavani

Abstract

Aim: The study aimed to analyze the effect of Sitagliptin with Glimepiride during the treatment to improve pancreatic beta-cells in T2DM patients. Beta cells are type of cell found in pancreatic islet and also synthesize, secrete the insulin and amylin. Sitagliptin is found to be maintaining the beta-cells function and glycaemic control in T2DM patients.

Place and Duration of Study: Sample: This study open label randomized T2DM patients, study was conducted at the, Felix multi-specialty hospital, Noida U.P with enrolled patients from 1st Oct, 2017 to 30st Sept, 2019.

Methodology: Randomly diabetes mellitus type-2 (T2DM) patients’ data is collected (110patients) for statistical analysis. For this study T2DM patients enrolled with age of 30-60 years, treated with Sitagliptin and Glimepiride once a day. The baseline of HbA1c >7.0% to <10.5% thus, the performed student t-test is to find out the significance role.

Results: The 110 patients are distributed in two groups: one Sitagliptin user group (n=62) and second Glimepiride user group (n=43). The sitagliptin treatments may also protect also beta cells as pancreas may not able to regenerate beta cell.

Conclusion: The sitagliptin treatments may also protect beta cells as pancreas may not able to regenerate beta cell.

Keywords:
Beta-cells, diabetes mellitus type-2, glimepiride, sitagliptin.

Article Details

How to Cite
Joshi, B., Yadav, P., & Bhavani, A. G. (2020). Effect of Sitagliptin and Glimepiride on Pancreatic Beta-Cells during the Treatment of Type-2 Diabetic Mellitus by Statistical Analysis. Journal of Pharmaceutical Research International, 32(29), 76-83. https://doi.org/10.9734/jpri/2020/v32i2930887
Section
Original Research Article

References

Tumer RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type-2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study Group (UKPDG). 2005-2012;281(21).

Dore JW, Thompson ME, Wilde CE, Sewell PF. Diet and oral anti-diabetic drugs and plasma sugar and insulin level in patient with maturity-onset diabetes mellitus, Br. Med. J. 1976;1:498-500.

Harman GA, Bergman A, Stevens C, el al. Effect of single oral dose of sitagliptin, a dipeptidyl peptidase-4 (DDP-4) inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type-2 diabetes. J. Clin. Endo. Crinol. Metab. 2006;91:4612-4619.

U.K prospective diabetes study 16. Overview of 6 years therapy of type-2 diabetes: A progressive disease Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249-1258.

Scheen AJ. Cardiovascular effects of gliptins. Nature Reviews Cardiology. 2013; 10:73-84.

Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, et al. safety and efficacy of treatments with sitagliptin od glipizide in patients with type-2 diabetes inadequately controlled on metformin: a 2-years study. Int. J. Clin. Pract. 2010;64(5):562-576.

Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitoaka M, Satoh J, Yeba D, et al. Efficacy and safety of sitagliptina compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥60 years. Diabetes Obes. Metab. 2017; 19(8):1188-1192.

Lindenmeyer A: Interventions to improve adherence to medication in people with type 2 diabetes mellitus: A review of the literature on the role of pharmacists. Journal of Clinical Pharmacy and Therapeutics. 2006;31(5):409-419.

Kerr D, Phillip M. Improved glycaemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006; 29:2730-2732.

Satos, Saisho Y, Kou K, Meguro S, Tanaka M, Irie J. Efficacy and safety of sitagliptin added to insulin in Janpanes patients with type-2 diabetes. 2015;10(3): e0121988.

Shi C, Zhang R, Bai R, Liu D, Wang Y, Zhang X, Wang H, Du J. Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type-2 diabetes. Clinics (Sao Paulo). 2019;74:e736.

Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: A major new class of oral antidiabetic drug. Diabetes, Obesity and Metabolism. 2007;9:153–5.

Bae EJ: Dipeptidyl peptidase-IV inhibitors in diabetes complication: Role of DDP-4 beyond glucose control. Arch Pharm. 2016;39(8):1114-1128.

Herman GA, Bergman A, Stevens C, Kotey P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-iv inhibitor, on incretin and plasma glucose levels with type-2 diabetes. J Clin Endocrinol Metab Dio. 2006;10:1210- 1009.

Mu J, Woods J, Zhou YP, et al. Chronic inhibition of DPP-4 with sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1696-1704.

Pasquel PJ, Gianchandani R, Rubin DJ. Efficacy of Sitagliptin for the hospital management of general medicine and surgery patients with type-2 diabetes. 2017;5:125-3.